Jacobs Levy Equity Management’s Thermo Fisher Scientific TMO Stock Holding History

Jacobs Levy Equity Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,921	Closed	-$12.4M	–	1165
2025 Q1	$12.4M	Buy	+24,921	New	+$13.5M	0.05%	299

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jacobs Levy Equity Management's TMO Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 24,921 shares — an estimated $12.4M sold.

Jacobs Levy Equity Management first reported a position in TMO in Q1 2025 and held it in 1 quarter. The position peaked at $12.4M in Q1 2025. 2,453 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

Jacobs Levy Equity Management reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 24,921 Thermo Fisher Scientific shares in Q2 2025, an estimated $12.4M.
Jacobs Levy Equity Management first reported a position in Thermo Fisher Scientific in Q1 2025 and held it in 1 quarter.
Jacobs Levy Equity Management's Thermo Fisher Scientific position peaked at $12.4M in Q1 2025.
2,453 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.